Bluejay Diagnostics 株価情報 (NASDAQ: BJDX)

最新ニュース Bluejay Diagnostics (NASDAQ:BJDX) 株価情報

Bluejay Diagnostics

Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.

Bluejay Diagnostics Inc

UBS analyst Stephen Ju maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Neutral and lowers the price target from $194 to $170.

News

Price Target

Analyst Ratings

EXPE

UBS Maintains Neutral on Expedia Group, Lowers Price Target to $170

German American Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GABC#NASDAQ">GABC</a>) reported quarterly earnings of $0.79 per share which beat the analyst consensus estimate of $0.66 by 19.7 percent. This is a 27.42 percent increase over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $81.41 million which beat the analyst consensus estimate of $79.56 million by 2.33 percent. This is a 33.87 percent increase over sales of $60.82 million the same period last year.

Earnings

Earnings Beats

GABC

German American Bancorp Q1 Adj. EPS $0.79 Beats $0.66 Estimate, Sales $81.41M Beat $79.56M Estimate

UBS analyst Brian Meredith maintains Goosehead Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) with a Buy and lowers the price target from $145 to $140.

GSHD

UBS Maintains Buy on Goosehead Insurance, Lowers Price Target to $140

UBS analyst Ashwani Verma maintains Harmony Biosciences Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>) with a Buy and lowers the price target from $55 to $48.

HRMY

UBS Maintains Buy on Harmony Biosciences Hldgs, Lowers Price Target to $48

Linkbancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNKB#NASDAQ">LNKB</a>) reported quarterly earnings of $0.20 per share which missed the analyst consensus estimate of $0.24 by 16.67 percent. This is a 25 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $39.09 million which beat the analyst consensus estimate of $32.48 million by 20.34 percent. This is a 46.88 percent increase over sales of $26.61 million the same period last year.

Earnings Misses

LNKB

Linkbancorp Q1 Adj. EPS $0.20 Misses $0.24 Estimate, Sales $39.09M Beat $32.48M Estimate

UBS analyst Stephen Ju maintains Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) with a Neutral and lowers the price target from $160 to $138.

ABNB

UBS Maintains Neutral on Airbnb, Lowers Price Target to $138

Broadway Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYFC#NASDAQ">BYFC</a>) reported quarterly losses of $(0.14) per share. This is a 600 percent decrease over losses of $(0.02) per share from the same period last year. The company reported $8.33 million in sales this quarter. This is a 6.42 percent increase over sales of $7.83 million the same period last year.

BYFC

Broadway Financial Q1 EPS $(0.14) Down From $(0.02) YoY, Sales $8.33M Up From $7.83M YoY

UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and lowers the price target from $25 to $22.

ACAD

UBS Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $22

UBS analyst Ashwani Verma maintains Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Neutral and lowers the price target from $38 to $33.

ALKS

UBS Maintains Neutral on Alkermes, Lowers Price Target to $33

WIIM

OKTA

Okta shares are trading higher after the company announced it will replace Berry Global Group in the S&P Midcap 400, effective before the opening of trading on Thursday, May 1

<a href="https://www.bloomberg.com/news/articles/2025-04-28/alibaba-rolls-out-latest-flagship-ai-model-in-post-deepseek-race">https://www.bloomberg.com/news/articles/2025-04-28/alibaba-rolls-out-latest-flagship-ai-model-in-post-deepseek-race</a>

General

BABA

'Alibaba Rolls Out Latest Flagship AI Model in Post-DeepSeek Race'- Bloomberg

Tevogen Bio Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares are ripping higher in Monday&#8217;s after-hours session after the company reaffirmed its <a href="https://www.benzinga.com/pressreleases/25/04/g45053606/tevogen-reaffirms-oncology-top-line-revenue-forecast-of-1-billion-in-launch-year-and-cumulative-5-">oncology pipeline revenue forecast</a>.
What Happened: After the market close on Monday, Tevogen Bio reaffirmed its oncology pipeline outlook, forecasting $1 billion in revenue in its launch year. The company also projected cumulative five-year estimated sales in the range of $10 billion and $14 billion. 
&#8220;With our intellectual property secured, Tevogen continues to build its U.S.-based cell therapy manufacturing capabilities, and I look forward to updating our shareholders on our forecasts and internal assets valuation,&#8221; said Ryan Saadi, founder and CEO of Tevogen Bio.
Tevogen Bio had a market cap of approximately $173.7 million as of Monday&#8217;s close. The company is set to hold its 2025 annual meeting of stockholders on June 23.
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/04/45053893/amkor-technology-shares-climb-after-q1-revenue-beats-q2-revenue-guidance-above-estimates">Amkor Technology Shares Climb After Q1 Revenue Beats, Q2 Revenue Guidance Above Estimates</a>
<h3 class="wp-block-heading">How To Buy TVGN Stock</h3>
By now you're likely curious about how to participate in the market for Tevogen Bio — be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> 
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading — either way it allows you to profit off of the share price decline.
TVGN Price Action: <a href="http://benzinga.com/quote/tvgn">Tevogen Bio shares</a> were up 39.76% after-hours, trading at $1.31 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a> data.
Photo: <a href="https://www.shutterstock.com/g/Timon+photography+world">T. Schneider</a>/Shutterstock.

Biotech

Guidance

After-Hours Center

Movers

TVGN

Tevogen Bio Holdings Stock Is Soaring After Hours: What's Going On?

UBS analyst Andrew Mok maintains Encompass Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) with a Buy and raises the price target from $117 to $130.

UBS Maintains Buy on Encompass Health, Raises Price Target to $130

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20250428-1477852/1477852_bery4.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20250428-1477852/1477852_bery4.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20250428-1477852/1477852_bery4.pdf</a>

Markets

BERY

Okta Will Replace Berry Global Group In The S&P MidCap 400 Effective Prior To The Opening Of Trading On Thursday, May 1

UBS analyst Brian Meredith maintains Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) with a Neutral and raises the price target from $303 to $304.

UBS Maintains Neutral on Chubb, Raises Price Target to $304

NXPL

NextPlat  Receives Nasdaq Letter Regarding Minimum Bid Requirements

UBS analyst Brian Meredith maintains The Hartford Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) with a Buy and raises the price target from $139 to $142.

UBS Maintains Buy on The Hartford Insurance Gr, Raises Price Target to $142

Evolv Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent. This is a 57.14 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $29.10 million which beat the analyst consensus estimate of $28.21 million by 3.17 percent. This is a 33.36 percent increase over sales of $21.82 million the same period last year.

EVLV

Evolv Technologies Q4 2024 Adj. EPS $(0.03) Beats $(0.06) Estimate, Sales $29.10M Beat $28.21M Estimate

Evolv Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 50 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $27.36 million which beat the analyst consensus estimate of $26.32 million by 3.95 percent. This is a 35.51 percent increase over sales of $20.19 million the same period last year.

Evolv Technologies Q3 2024 Adj. EPS $(0.04) Beats $(0.06) Estimate, Sales $27.36M Beat $26.32M Estimate

Capital Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBNK#NASDAQ">CBNK</a>) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $0.72 by 22.22 percent. This is a 72.55 percent increase over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $58.60 million which beat the analyst consensus estimate of $57.43 million by 2.03 percent. This is a 42.99 percent increase over sales of $40.98 million the same period last year.

Comments

Bluejay Diagnostics

ニュース

最新ニュース Bluejay Diagnostics (NASDAQ:BJDX) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル